Bezzio, C.; Vernero, M.; Ribaldone, D.G.; Alimenti, E.; Manes, G.; Saibeni, S.
Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis. Cancers 2023, 15, 2197.
https://doi.org/10.3390/cancers15082197
AMA Style
Bezzio C, Vernero M, Ribaldone DG, Alimenti E, Manes G, Saibeni S.
Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis. Cancers. 2023; 15(8):2197.
https://doi.org/10.3390/cancers15082197
Chicago/Turabian Style
Bezzio, Cristina, Marta Vernero, Davide Giuseppe Ribaldone, Eleonora Alimenti, Gianpiero Manes, and Simone Saibeni.
2023. "Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis" Cancers 15, no. 8: 2197.
https://doi.org/10.3390/cancers15082197
APA Style
Bezzio, C., Vernero, M., Ribaldone, D. G., Alimenti, E., Manes, G., & Saibeni, S.
(2023). Cancer Risk in Patients Treated with the JAK Inhibitor Tofacitinib: Systematic Review and Meta-Analysis. Cancers, 15(8), 2197.
https://doi.org/10.3390/cancers15082197